189 related articles for article (PubMed ID: 26430825)
21. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
Bates RD; Nahata MC; Jones JW; McCoy K; Young G; Cox S; Barson WJ
Chest; 1997 Nov; 112(5):1208-13. PubMed ID: 9367459
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis.
Touw DJ; Knox AJ; Smyth A
J Cyst Fibros; 2007 Sep; 6(5):327-33. PubMed ID: 17276147
[TBL] [Abstract][Full Text] [Related]
23. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
Bragonier R; Brown NM
J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic target attainment with high-dose extended-interval tobramycin therapy in patients with cystic fibrosis.
DeGrado JR; Cios D; Greenwood BC; Kubiak DW; Szumita PM
J Chemother; 2014 Apr; 26(2):101-4. PubMed ID: 24090527
[TBL] [Abstract][Full Text] [Related]
25. Individualization of tobramycin dosage in patients with cystic fibrosis.
Hsu MC; Aguila HA; Schmidt VL; Munzenberger PJ; Kauffman RE; Polgar G
Pediatr Infect Dis; 1984; 3(6):526-9. PubMed ID: 6440126
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
Staubes BA; Metzger NL; Walker SD; Peasah SK
Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
[TBL] [Abstract][Full Text] [Related]
27. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
28. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS.
Sands D; Sapiejka E; Gąszczyk G; Mazurek H;
J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961
[TBL] [Abstract][Full Text] [Related]
29. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
30. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
[TBL] [Abstract][Full Text] [Related]
31. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
[No Abstract] [Full Text] [Related]
32. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Glass S; Plant ND; Spencer DA
J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
Antimicrob Agents Chemother; 2013 Oct; 57(10):5175-7. PubMed ID: 23896470
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis.
Alghanem SS; Touw DJ; Thomson AH
J Antimicrob Chemother; 2019 Aug; 74(8):2311-2317. PubMed ID: 31322695
[TBL] [Abstract][Full Text] [Related]
35. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
[TBL] [Abstract][Full Text] [Related]
36. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries.
Hoey LL; Tschida SJ; Rotschafer JC; Guay DR; Vance-Bryan K
J Burn Care Rehabil; 1997; 18(2):116-24. PubMed ID: 9095420
[TBL] [Abstract][Full Text] [Related]
37. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
38. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation.
Downes KJ; Grim A; Shanley L; Rubenstein RC; Zuppa AF; Gastonguay MR
Antimicrob Agents Chemother; 2022 May; 66(5):e0237721. PubMed ID: 35481751
[TBL] [Abstract][Full Text] [Related]
39. Suboptimal aminoglycoside dosing in critically ill patients.
Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
Hennig S; Standing JF; Staatz CE; Thomson AH
Clin Pharmacokinet; 2013 Apr; 52(4):289-301. PubMed ID: 23420517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
